Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 29

1.

Effects of age, BMI and sex on the glial cell marker TSPO - a multicentre [11C]PBR28 HRRT PET study.

Tuisku J, Plavén-Sigray P, Gaiser EC, Airas L, Al-Abdulrasul H, Brück A, Carson RE, Chen MK, Cosgrove KP, Ekblad L, Esterlis I, Farde L, Forsberg A, Halldin C, Helin S, Kosek E, Lekander M, Lindgren N, Marjamäki P, Rissanen E, Sucksdorff M, Varrone A; HRRT [11C ]PBR28 study group, Collste K, Gallezot JD, Hillmer A, Huang Y, Höglund CO, Johansson J, Jucaite A, Lampa J, Nabulsi N, Pittman B, Sandiego CM, Stenkrona P, Rinne J, Matuskey D, Cervenka S.

Eur J Nucl Med Mol Imaging. 2019 Oct;46(11):2329-2338. doi: 10.1007/s00259-019-04403-7. Epub 2019 Jul 30.

2.

A PET study in healthy subjects of brain exposure of 11C-labelled osimertinib - A drug intended for treatment of brain metastases in non-small cell lung cancer.

Varrone A, Varnäs K, Jucaite A, Cselényi Z, Johnström P, Schou M, Vazquez-Romero A, Moein MM, Halldin C, Brown AP, Vishwanathan K, Farde L.

J Cereb Blood Flow Metab. 2019 Apr 20:271678X19843776. doi: 10.1177/0271678X19843776. [Epub ahead of print]

PMID:
31006308
3.

Test-retest reliability and convergent validity of (R)-[11C]PK11195 outcome measures without arterial input function.

Plavén-Sigray P, Matheson GJ, Cselényi Z, Jucaite A, Farde L, Cervenka S.

EJNMMI Res. 2018 Nov 29;8(1):102. doi: 10.1186/s13550-018-0455-8.

4.

PET imaging of [11C]PBR28 in Parkinson's disease patients does not indicate increased binding to TSPO despite reduced dopamine transporter binding.

Varnäs K, Cselényi Z, Jucaite A, Halldin C, Svenningsson P, Farde L, Varrone A.

Eur J Nucl Med Mol Imaging. 2019 Feb;46(2):367-375. doi: 10.1007/s00259-018-4161-6. Epub 2018 Oct 1.

5.

GABAA receptor occupancy by subtype selective GABAAα2,3 modulators: PET studies in humans.

Jucaite A, Cselényi Z, Lappalainen J, McCarthy DJ, Lee CM, Nyberg S, Varnäs K, Stenkrona P, Halldin C, Cross A, Farde L.

Psychopharmacology (Berl). 2017 Feb;234(4):707-716. doi: 10.1007/s00213-016-4506-4. Epub 2016 Dec 24.

6.

In vivo evidence of a functional association between immune cells in blood and brain in healthy human subjects.

Kanegawa N, Collste K, Forsberg A, Schain M, Arakawa R, Jucaite A, Lekander M, Olgart Höglund C, Kosek E, Lampa J, Halldin C, Farde L, Varrone A, Cervenka S.

Brain Behav Immun. 2016 May;54:149-157. doi: 10.1016/j.bbi.2016.01.019. Epub 2016 Jan 25.

PMID:
26820224
7.

Effect of the myeloperoxidase inhibitor AZD3241 on microglia: a PET study in Parkinson's disease.

Jucaite A, Svenningsson P, Rinne JO, Cselényi Z, Varnäs K, Johnström P, Amini N, Kirjavainen A, Helin S, Minkwitz M, Kugler AR, Posener JA, Budd S, Halldin C, Varrone A, Farde L.

Brain. 2015 Sep;138(Pt 9):2687-700. doi: 10.1093/brain/awv184. Epub 2015 Jul 1.

PMID:
26137956
8.

A PET study comparing receptor occupancy by five selective cannabinoid 1 receptor antagonists in non-human primates.

Hjorth S, Karlsson C, Jucaite A, Varnäs K, Wählby Hamrén U, Johnström P, Gulyás B, Donohue SR, Pike VW, Halldin C, Farde L.

Neuropharmacology. 2016 Feb;101:519-30. doi: 10.1016/j.neuropharm.2015.03.002. Epub 2015 Mar 17.

9.

Norepinephrine transporter occupancy in the human brain after oral administration of quetiapine XR.

Nyberg S, Jucaite A, Takano A, Kågedal M, Cselényi Z, Halldin C, Farde L.

Int J Neuropsychopharmacol. 2013 Nov;16(10):2235-44. doi: 10.1017/S1461145713000680. Epub 2013 Jul 1.

PMID:
23809226
10.

A randomized, double-blind, placebo-controlled crossover study of α4β 2* nicotinic acetylcholine receptor agonist AZD1446 (TC-6683) in adults with attention-deficit/hyperactivity disorder.

Jucaite A, Öhd J, Potter AS, Jaeger J, Karlsson P, Hannesdottir K, Boström E, Newhouse PA, Paulsson B.

Psychopharmacology (Berl). 2014 Mar;231(6):1251-65. doi: 10.1007/s00213-013-3116-7. Epub 2013 May 3.

11.

A PET study with [11C]AZ10419369 to determine brain 5-HT1B receptor occupancy of zolmitriptan in healthy male volunteers.

Varnäs K, Jučaite A, McCarthy DJ, Stenkrona P, Nord M, Halldin C, Farde L, Kanes S.

Cephalalgia. 2013 Jul;33(10):853-60. doi: 10.1177/0333102413476372. Epub 2013 Feb 19.

PMID:
23430984
12.

Radiolabeling of the cannabinoid receptor agonist AZD1940 with carbon-11 and PET microdosing in non-human primate.

Schou M, Varnäs K, Jucaite A, Gulyás B, Halldin C, Farde L.

Nucl Med Biol. 2013 Apr;40(3):410-4. doi: 10.1016/j.nucmedbio.2012.10.011. Epub 2013 Jan 22.

PMID:
23352602
13.

AZD5213: a novel histamine H3 receptor antagonist permitting high daytime and low nocturnal H3 receptor occupancy, a PET study in human subjects.

Jucaite A, Takano A, Boström E, Jostell KG, Stenkrona P, Halldin C, Segerdahl M, Nyberg S.

Int J Neuropsychopharmacol. 2013 Jul;16(6):1231-9. doi: 10.1017/S1461145712001411. Epub 2012 Dec 10.

PMID:
23217964
14.

Individual differences in the proneness to have flow experiences are linked to dopamine D2-receptor availability in the dorsal striatum.

de Manzano Ö, Cervenka S, Jucaite A, Hellenäs O, Farde L, Ullén F.

Neuroimage. 2013 Feb 15;67:1-6. doi: 10.1016/j.neuroimage.2012.10.072. Epub 2012 Nov 2.

15.

Melatonin secretion in children with epilepsy.

Praninskiene R, Dumalakiene I, Kemezys R, Mauricas M, Jucaite A.

Epilepsy Behav. 2012 Nov;25(3):315-22. doi: 10.1016/j.yebeh.2012.08.012. Epub 2012 Oct 24.

PMID:
23103303
16.

Kinetic analysis and test-retest variability of the radioligand [11C](R)-PK11195 binding to TSPO in the human brain - a PET study in control subjects.

Jučaite A, Cselényi Z, Arvidsson A, Ahlberg G, Julin P, Varnäs K, Stenkrona P, Andersson J, Halldin C, Farde L.

EJNMMI Res. 2012 Apr 23;2:15. doi: 10.1186/2191-219X-2-15.

17.

Diurnal melatonin patterns in children: ready to apply in clinical practice?

Praninskienė R, Dumalakienė I, Kemežys R, Mauricas M, Jučaitė A.

Pediatr Neurol. 2012 Feb;46(2):70-6. doi: 10.1016/j.pediatrneurol.2011.11.018.

PMID:
22264699
18.

Quantitative PET analyses of regional [11C]PE2I binding to the dopamine transporter--application to juvenile myoclonic epilepsy.

Odano I, Varrone A, Savic I, Ciumas C, Karlsson P, Jucaite A, Halldin C, Farde L.

Neuroimage. 2012 Feb 15;59(4):3582-93. doi: 10.1016/j.neuroimage.2011.10.067. Epub 2011 Oct 28.

PMID:
22056530
19.

Comparison of D₂ dopamine receptor occupancy after oral administration of quetiapine fumarate immediate-release and extended-release formulations in healthy subjects.

Nord M, Nyberg S, Brogren J, Jucaite A, Halldin C, Farde L.

Int J Neuropsychopharmacol. 2011 Nov;14(10):1357-66. doi: 10.1017/S1461145711000514. Epub 2011 Apr 11.

20.

Age-related reduction in dopamine D1 receptors in the human brain: from late childhood to adulthood, a positron emission tomography study.

Jucaite A, Forssberg H, Karlsson P, Halldin C, Farde L.

Neuroscience. 2010 Apr 28;167(1):104-10. doi: 10.1016/j.neuroscience.2010.01.034. Epub 2010 Jan 28.

PMID:
20109534
21.

Changes in cortical dopamine D1 receptor binding associated with cognitive training.

McNab F, Varrone A, Farde L, Jucaite A, Bystritsky P, Forssberg H, Klingberg T.

Science. 2009 Feb 6;323(5915):800-2. doi: 10.1126/science.1166102.

22.

Reduced dopamine transporter binding in patients with juvenile myoclonic epilepsy.

Ciumas C, Wahlin TB, Jucaite A, Lindstrom P, Halldin C, Savic I.

Neurology. 2008 Sep 9;71(11):788-94. doi: 10.1212/01.wnl.0000316120.70504.d5. Epub 2008 May 7.

PMID:
18463366
23.

Quantitative analyses of regional [11C]PE2I binding to the dopamine transporter in the human brain: a PET study.

Jucaite A, Odano I, Olsson H, Pauli S, Halldin C, Farde L.

Eur J Nucl Med Mol Imaging. 2006 Jun;33(6):657-68. Epub 2006 Mar 3.

PMID:
16514530
24.
25.

A cross-validation study on the relationship between central D2 receptor occupancy and serum perphenazine concentration.

Talvik M, Nordström AL, Larsen NE, Jucaite A, Cervenka S, Halldin C, Farde L.

Psychopharmacology (Berl). 2004 Sep;175(2):148-53. Epub 2004 Mar 6.

PMID:
15007534
26.

Deficient coordination of associated postural adjustments during a lifting task in children with neurodevelopmental disorders.

Jucaite A, Fernell E, Forssberg H, Hadders-Algra M.

Dev Med Child Neurol. 2003 Nov;45(11):731-42.

27.

[Dopaminergic modulation of cerebral activity and cognitive functions].

Jucaite A.

Medicina (Kaunas). 2002;38(4):357-62. Review. Lithuanian.

28.

Shared memory representations for programming of lifting movements and associated whole body postural adjustments in humans.

Forssberg H, Jucaite A, Hadders-Algra M.

Neurosci Lett. 1999 Sep 24;273(1):9-12.

PMID:
10505639
29.

Investigations of pneumocystosis among humans and rodents in Lithuania.

Bajoriniené DJ, Jucaite A.

Wiad Parazytol. 1997;43(1):53-9.

PMID:
9259608

Supplemental Content

Loading ...
Support Center